Radiofrequency Ablation of Ectopic Atrial Tachycardia

Congenital Disorders Clinical Trial

Official title:

A Retrospective Review of Outcomes Related to Radiofrequency Ablation of Ectopic Atrial Tachycardia

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00267982
• Other study ID #: 03-064
• Status: Terminated
• Phase: N/A
• First received: December 20, 2005
• Last updated: July 5, 2011
• Start date: August 1992
• Est. completion date: February 2008

Study information

• Verified date: June 2011
• Source: Children's Healthcare of Atlanta
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Observational

Clinical Trial Summary

A retrospective chart review will be performed on 50 patients who received RFA for the treatment of EAT between August 1992 and August 2003 at Children's Healthcare of Atlanta.

The use of the CARTO/Biosense catheter has improved outcomes with decreased radiation exposure to patients.

Description:

Ectopic Atrial Tachycardia (EAT) is a relatively rare arrhythmia in the pediatric population. It is defined by a run of more than 3 premature atrial contractions together. In EAT, the arrhythmia tends to increase in rate over a period of time and then slows down gradually to a normal rhythm. Ectopic Atrial Tachycardia (EAT) is mostly encountered in patients with structurally normal hearts however, occasionally physicians do observe this type of disorder in children following surgery for congenital heart defects. Current reports suggest that EAT occurs in approximately 1 in 10,000 children (Hamilton, 2002).

Children with EAT usually present with a multitude of symptoms. The most common symptoms associated with pediatric EAT are palpitations, chest pain, lightheadedness, presyncope, and dyspnea. Other symptoms can include exercise intolerance and congestive heart failure. These are usually late manifestations. In the patients with tachycardia induced CM, the time of development of CM is dependent on the rate and duration of the tachycardia however, in most cases, dilation is present upon diagnosis. This CM can be reversed with successful treatment of the arrhythmia.

The treatment for chronic EAT includes medications such as adenosine and for difficult to control cases, Radiofrequency Ablation (RFA). RF ablation has been successful in curing EAT, with success rates ranging from 75-100%. It has been shown that the complication rates are similar to other RF ablation procedures, with a higher risk of recurrence (Hamilton, 2002).

At Children's Healthcare of Atlanta, the cardiac catheterization lab performs approximately 10 Radiofrequency ablations for EAT each year. The goal of this retrospective review is to assess the frequency of recurrence of the EAT among a subset of patients receiving treatment between August 1992 - August 2003

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 25
• Est. completion date: February 2008
• Est. primary completion date: August 2003
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A to 21 Years

Eligibility

Inclusion Criteria:

• 50 patients who received RFA for treatment of EAT between August 2992 and August 2003

• Treatment at Children's Healthcare of Atlanta

Exclusion Criteria:

• those who do not meet inclusion criteria

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Congenital Disorders
• Tachycardia

Locations

Country	Name	City	State
United States	Children's Healthcare of Atlanta	Atlanta	Georgia

Sponsors (1)

Lead Sponsor	Collaborator
Children's Healthcare of Atlanta

Country where clinical trial is conducted

United States,